Quick Answer
GoodRx Holdings, Inc. reported Total Revenue of $796.85 million for the year ending 2025.
- GoodRx Holdings, Inc. showed an increase of +0.6% in Total Revenue from 2024 to 2025.
- This data is from GoodRx Holdings, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2019: $101.75 million | Q1 2020: $133.41 million | Q2 2020: $123.30 million | Q3 2020: $140.45 million | Q1 2021: $160.43 million | Q2 2021: $176.64 million | Q3 2021: $195.10 million | Q1 2022: $203.33 million | Q2 2022: $191.80 million | Q3 2022: $187.32 million | Q1 2023: $183.99 million | Q2 2023: $189.68 million | Q3 2023: $179.96 million | Q1 2024: $197.88 million | Q2 2024: $200.61 million | Q3 2024: $195.25 million | Q1 2025: $202.97 million | Q2 2025: $203.07 million | Q3 2025: $196.03 million.
- Over the full 8 years of available data (2018 to 2025), GoodRx Holdings, Inc.'s Total Revenue has grown by 219.4%.
- Historical annual values: Fiscal year 2025: $796.85 million | Fiscal year 2024: $792.32 million | Fiscal year 2023: $750.27 million | Fiscal year 2022: $766.55 million | Fiscal year 2021: $745.42 million | Fiscal year 2020: $550.70 million | Fiscal year 2019: $388.22 million | Fiscal year 2018: $249.52 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: